Research Progress on Clinical Diagnosis for Lung Metastases from Differentiated Thyroid Carcinoma_Journal of Biomedical Engineering

Authors：

LIHuanhuan ,  LISuping , YOUJinhui

Department of Nuclear Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China;

Corresponding?author：

LISuping, Email: suping7273@163.com

Keywords：

differentiated thyroid cancer (DTC); lung metastases; radioiodine; diagnosis

DOI：

10.7507/1001-5515.20140179

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Lung metastases are more common in metastatic disease in differentiated thyroid carcinoma (DTC). Because of its insidious onset and slow development, clinical diagnosis is relatively difficult. Some possible diagnostic methods for detecting the lung metastasis of DTC including serological examination, radionuclide imaging and other medical imaging patterns are discussed in this paper. The progress and the current situation about investigation of those modalities which are in the early diagnosis, recurrent and clinical evaluation for the lung metastasis of DTC are briefly reviewed. Therefore, it is expected to promote DTC with lung metastasis to a higher diagnostic level.

Citation： LIHuanhuan, LISuping, YOUJinhui. Research Progress on Clinical Diagnosis for Lung Metastases from Differentiated Thyroid Carcinoma. Journal of Biomedical Engineering, 2014, 31(4): 950-954. doi: 10.7507/1001-5515.20140179 Copy

1.	楊愛民,薛建軍,高蕊,等.¹³¹碘全身顯像、甲狀腺球蛋白測定及頸部超聲檢查在分化型甲狀腺癌¹³¹碘治療隨訪中的意義[J].現代腫瘤醫學,2010,18(3):471-473.
2.	COOPER D S, DOHERTY G M, HAUGEN B R, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.
3.	李少華,王自正,邵國強,等.抗甲狀腺球蛋白抗體18F-FDG符合線路顯像在分化型甲狀腺癌隨訪中的臨床應用[J].中國醫學影像技術,2008,24(9):1456-1468.
4.	GREWAL R K, TUTTLE R M, FOX J, et al. The effect of posttherapy ¹³¹I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer[J]. J Nucl Med, 2010, 51(9): 1361-1367.
5.	OH J R, BYUN B H, HONG S P, et al. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8): 1459-1468.
6.	PAPATHANASSIOU D, BRUNA-MURAILLE C, LIEHN J C, et al. Positron emission tomography in oncology: present and future of PET and PET/CT[J]. Critical Reviews in Oncology/Hematology, 2009, 72(3): 239-254.
7.	MA C, XIE J, LOU Y, et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis[J]. European Journal of Endocrinology /European Federation of Endocrine Societies, 2010, 163(2): 177-183.
8.	KIM M H, H O J, KO S H, et al. Role of[(18F)]-flourodeoxy-D-glucose Positron Emission Tomography and Computer Tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive Iodine ablation therapy[J]. Thyroid, 2012, 22(2): 157-164.
9.	SEO Y L, YOON D Y, BAEK S, et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer)[J]. Eur Radiol, 2012, 22(10): 2246-2254.
10.	AHN B C, LEE S W, LEE J, et al. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer[J]. Thyroid, 2011, 21(5): 555-558.
11.	DUFOUR D R. Thyroglobulin antibodies--failing the test[J]. J Clin Endocrinol Metab, 2011, 96(5): 1276-1278.
12.	潘明志,趙波灃,楊小川.¹³¹I-WBS、Tg和X線胸片診斷分化型甲狀腺癌肺轉移灶的比較研究[J].華西醫學,2005,20(2):259-260.
13.	SEO J H, LEE S W, AHN B C, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT[J]. Clin Endocrinol (Oxf), 2010, 72(4): 558-563.
14.	譚天秩.臨床核醫學(第二十二章)[M]. 第2版.北京:人民衛生出版社,2003:1277-1278.
15.	KIM E S, LIM D J, BAEK K H, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules[J]. Thyroid, 2010, 20(8): 885-891.
16.	KOHLFUERST S, IGERC I, LOBNIG M, et al. Posttherapeutic ¹³¹I SPECT/CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 886-893.
17.	SPANU A, SOLINAS M E, CHESSA F, et al. ¹³¹I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging[J]. J Nucl Med, 2009, 50(2): 184-190.
18.	CHEN L, LUO Q, SHEN Y, et al. Incremental value of ¹³¹I SPECT/CT in the management of patients with differentiated thyroid carcinoma[J]. J Nucl Med, 2008, 49(12): 1952-1957.
19.	郭一玲,陳佐偉,張英男,等.¹³¹I-SPECT/CT融合顯像對分化型甲狀腺癌術后診斷臨床價值分析[J].現代腫瘤醫學,2009,17(12):2297-2298.
20.	吳震宇,王輝.分化型甲狀腺癌不同部位轉移灶¹³¹I-SPECT/CT影像學數據分析[J].上海交通大學學報:醫學版,2011,31(8):1154-1158.
21.	WONG K K, SISSON J C, KORAL K F, et al. Staging of differentiated thyroid carcinoma using diagnostic ¹³¹I SPECT/CT[J]. Am J Roentgenol, 2010, 195(3): 730-736.
22.	李曉曦.甲狀腺結節的影像學診斷[J].中國實用外科雜志,2010,30(10):886-888.
23.	KANEKO K, ABE K, BABA S, et al. Can calcification predict ¹³¹I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving ¹³¹I therapy? Comparison of CT, ¹³¹I WBS and ¹⁸F-FDG PET/CT[J]. Eur Radiol, 2010, 20(2): 477-483.
24.	鹿存芝,王躍濤,曹蘇生,等.PET/CT診斷分化型甲狀腺癌失分化患者復發及轉移灶[J].中國醫學影像技術,2009,25(8):1470-1472.
25.	LONDON K, LIN M. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer[J]. Ann Surg Oncol, 2011, 18(1): 291-292.
26.	KIM S J, LEE T H, KIM I J, et al. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin[J]. Eur J Radiol, 2009, 70(1): 17-24.
27.	SCHLOSSER J, PALIOU M, BRAVO-VERA R, et al. False positive uptake in post-treatment iodine-131 whole-body scans secondary to contamination[J]. Thyroid, 2007, 17(1): 81-82.

1. 楊愛民,薛建軍,高蕊,等.¹³¹碘全身顯像、甲狀腺球蛋白測定及頸部超聲檢查在分化型甲狀腺癌¹³¹碘治療隨訪中的意義[J].現代腫瘤醫學,2010,18(3):471-473.
2. COOPER D S, DOHERTY G M, HAUGEN B R, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.
3. 李少華,王自正,邵國強,等.抗甲狀腺球蛋白抗體18F-FDG符合線路顯像在分化型甲狀腺癌隨訪中的臨床應用[J].中國醫學影像技術,2008,24(9):1456-1468.
4. GREWAL R K, TUTTLE R M, FOX J, et al. The effect of posttherapy ¹³¹I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer[J]. J Nucl Med, 2010, 51(9): 1361-1367.
5. OH J R, BYUN B H, HONG S P, et al. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8): 1459-1468.
6. PAPATHANASSIOU D, BRUNA-MURAILLE C, LIEHN J C, et al. Positron emission tomography in oncology: present and future of PET and PET/CT[J]. Critical Reviews in Oncology/Hematology, 2009, 72(3): 239-254.
7. MA C, XIE J, LOU Y, et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis[J]. European Journal of Endocrinology /European Federation of Endocrine Societies, 2010, 163(2): 177-183.
8. KIM M H, H O J, KO S H, et al. Role of[(18F)]-flourodeoxy-D-glucose Positron Emission Tomography and Computer Tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive Iodine ablation therapy[J]. Thyroid, 2012, 22(2): 157-164.
9. SEO Y L, YOON D Y, BAEK S, et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer)[J]. Eur Radiol, 2012, 22(10): 2246-2254.
10. AHN B C, LEE S W, LEE J, et al. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer[J]. Thyroid, 2011, 21(5): 555-558.
11. DUFOUR D R. Thyroglobulin antibodies--failing the test[J]. J Clin Endocrinol Metab, 2011, 96(5): 1276-1278.
12. 潘明志,趙波灃,楊小川.¹³¹I-WBS、Tg和X線胸片診斷分化型甲狀腺癌肺轉移灶的比較研究[J].華西醫學,2005,20(2):259-260.
13. SEO J H, LEE S W, AHN B C, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT[J]. Clin Endocrinol (Oxf), 2010, 72(4): 558-563.
14. 譚天秩.臨床核醫學(第二十二章)[M]. 第2版.北京:人民衛生出版社,2003:1277-1278.
15. KIM E S, LIM D J, BAEK K H, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules[J]. Thyroid, 2010, 20(8): 885-891.
16. KOHLFUERST S, IGERC I, LOBNIG M, et al. Posttherapeutic ¹³¹I SPECT/CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 886-893.
17. SPANU A, SOLINAS M E, CHESSA F, et al. ¹³¹I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging[J]. J Nucl Med, 2009, 50(2): 184-190.
18. CHEN L, LUO Q, SHEN Y, et al. Incremental value of ¹³¹I SPECT/CT in the management of patients with differentiated thyroid carcinoma[J]. J Nucl Med, 2008, 49(12): 1952-1957.
19. 郭一玲,陳佐偉,張英男,等.¹³¹I-SPECT/CT融合顯像對分化型甲狀腺癌術后診斷臨床價值分析[J].現代腫瘤醫學,2009,17(12):2297-2298.
20. 吳震宇,王輝.分化型甲狀腺癌不同部位轉移灶¹³¹I-SPECT/CT影像學數據分析[J].上海交通大學學報:醫學版,2011,31(8):1154-1158.
21. WONG K K, SISSON J C, KORAL K F, et al. Staging of differentiated thyroid carcinoma using diagnostic ¹³¹I SPECT/CT[J]. Am J Roentgenol, 2010, 195(3): 730-736.
22. 李曉曦.甲狀腺結節的影像學診斷[J].中國實用外科雜志,2010,30(10):886-888.
23. KANEKO K, ABE K, BABA S, et al. Can calcification predict ¹³¹I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving ¹³¹I therapy? Comparison of CT, ¹³¹I WBS and ¹⁸F-FDG PET/CT[J]. Eur Radiol, 2010, 20(2): 477-483.
24. 鹿存芝,王躍濤,曹蘇生,等.PET/CT診斷分化型甲狀腺癌失分化患者復發及轉移灶[J].中國醫學影像技術,2009,25(8):1470-1472.
25. LONDON K, LIN M. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer[J]. Ann Surg Oncol, 2011, 18(1): 291-292.
26. KIM S J, LEE T H, KIM I J, et al. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin[J]. Eur J Radiol, 2009, 70(1): 17-24.
27. SCHLOSSER J, PALIOU M, BRAVO-VERA R, et al. False positive uptake in post-treatment iodine-131 whole-body scans secondary to contamination[J]. Thyroid, 2007, 17(1): 81-82.

Previous Article
Research Progress in Multidetector-row Computed Tomographic Presentations and Their Anatomic-pathologic Features of Aortic Dissection after Endovascular Graft Exclusion or Combined Surgical and Endovascular Treatment

Journal of Biomedical Engineering

Research Progress on Clinical Diagnosis for Lung Metastases from Differentiated Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content